Multiple low-dose challenges in a Rhesus Macaque AIDS vaccine trial result in an evolving host response that affects protective outcome

Clinical and Vaccine Immunology

Volumn 21, Issue 12, 2014, Pages 1650-1660

  Selinger, Christian ^a   Strbo, Natasa ^b   Gonzalez, Louis ^b   Aicher, Lauri ^a   Weiss, Jeffrey M ^a   Law, G Lynn ^a   Palermo, Robert E ^a   Vaccari, Monica ^c   Franchini, Genoveffa ^c   Podack, Eckhard R ^b   Katze, Michael G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIBODY;

ANIMAL; BLOOD; FEMALE; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MALE; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; FEMALE; HOST-PATHOGEN INTERACTIONS; MACACA MULATTA; MALE; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

EID: 84914125479     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00455-14     Document Type: Article

References (45)

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871. http://dx.doi.org/10.1126/science.6189183.
2. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, White G, Foster P, Markham PD. 1984. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500-503. http://dx.doi.org/10.1126/science.6200936.
3. VanCott TC, Bethke FR, Burke DS, Redfield RR, Birx DL. 1995. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155:4100-4110.
4. Haynes BF. 1996. New frontiers of immunotherapy for HIV. Lancet 348: 1531-1532.
5. Novitsky V, Lagakos S, Herzig M, Bonney C, Kebaabetswe L, Rossenkhan R, Nkwe D, Margolin L, Musonda R, Moyo S, Woldegabriel E, van Widenfelt E, Makhema J, Essex M. 2009. Evolution of proviral gp120 over the first year of HIV-1 subtype C infection. Virology 383:47-59. http://dx.doi.org/10.1016/j.virol.2008.09.017.
6. Tyagi M, Bukrinsky M. 2012. Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol. Med. 18:1096-1108. http://dx.doi.org/10.2119/molmed.2012.00194.
7. Strbo N, Garcia-Soto A, Schreiber TH, Podack ER. 2013. Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases. Immunol. Res. 57:311-325. http://dx.doi.org/10.1007/s12026-013-8468-x.
8. Cho BK, Palliser D, Guillen E, Wisniewski J, Young RA, Chen J, Eisen HN. 2000. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity 12:263-272. http://dx.doi.org/10.1016/S1074-7613(00)80179-X.
9. Palliser D, Guillen E, Ju M, Eisen HN. 2005. Multiple intracellular routes in the cross-presentation of a soluble protein by murine dendritic cells. J. Immunol. 174:1879-1887. http://dx.doi.org/10.4049/jimmunol.174.4.1879.
10. Binder RJ, Srivastava PK. 2005. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8 T cells. Nat. Immunol. 6:593-599. http://dx.doi.org/10.1038/ni1201.
11. Yamazaki K, Nguyen T, Podack ER. 1999. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J. Immunol. 163: 5178-5182.
12. Oizumi S, Strbo N, Pahwa S, Deyev V, Podack ER. 2007. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes. J. Immunol. 179:2310-2317. http://dx.doi.org/10.4049/jimmunol.179.4.2310.
13. Strbo N, Pahwa S, Kolber MA, Gonzalez L, Fisher E, Podack ER. 2010. Cell-secreted gp96-Ig-peptide complexes induce lamina propria and intraepithelial CD8 cytotoxic T lymphocytes in the intestinal mucosa. Mucosal Immunol. 3:182-192. http://dx.doi.org/10.1038/mi.2009.127.
14. Strbo N, Vaccari M, Pahwa S, Kolber MA, Fisher E, Gonzalez L, Doster MN, Hryniewicz A, Felber BK, Pavlakis GN, Franchini G, Podack ER. 2011. gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa. Vaccine 29:2619-2625. http://dx.doi.org/10.1016/j.vaccine.2011.01.044.
15. Strbo N, Vaccari M, Pahwa S, Kolber MA, Doster MN, Fisher E, Gonzalez L, Stablein D, Franchini G, Podack ER. 2013. Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus. J. Immunol. 190:2495-2499. http://dx.doi.org/10.4049/jimmunol.1202655.
16. Li C, Bankhead A, 3rd, Eisfeld AJ, Hatta Y, Jeng S, Chang JH, Aicher LD, Proll S, Ellis AL, Law GL, Waters KM, Neumann G, Katze MG, McWeeney S, Kawaoka Y. 2011. Host regulatory network response to infection with highly pathogenic H5N1 avian influenza virus. J. Virol. 85:10955-10967. http://dx.doi.org/10.1128/JVI.05792-11.
17. Smyth G. 2005. Limma: linear models for microarray data, p 397-420. In Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S (ed), Bioinformatics and computational biology solutions using R and Bioconductor. Springer, New York, NY.
18. Regoes RR. 2012. The role of exposure history on HIV acquisition: insights from repeated low-dose challenge studies. PLoS Comput. Biol. 8:e1002767. http://dx.doi.org/10.1371/journal.pcbi.1002767.
19. Verhoeven D, George MD, Hu W, Dang AT, Smit-McBride Z, Reay E, Macal M, Fenton A, Sankaran-Walters S, Dandekar S. 2014. Enhanced innate antiviral gene expression, IFN-alpha, and cytolytic responses are predictive of mucosal immune recovery during simian immunodeficiency virus infection. J. Immunol. 192:3308-3318. http://dx.doi.org/10.4049/jimmunol.1302415.
20. Harty RN, Pitha PM, Okumura A. 2009. Antiviral activity of innate immune protein ISG15. J. Innate Immun. 1:397-404. http://dx.doi.org/10.1159/000226245.
21. Zhou Z, Wang N, Woodson SE, Dong Q, Wang J, Liang Y, Rijnbrand R, Wei L, Nichols JE, Guo J-T, Holbrook MR, Lemon SM, Li K. 2011. Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology 409:175-188. http://dx.doi.org/10.1016/j.virol.2010.10.008.
22. Espert L, Degols G, Lin YL, Vincent T, Benkirane M, Mechti N. 2005. Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1. J. Gen. Virol. 86:2221-2229. http://dx.doi.org/10.1099/vir.0.81074-0.
23. Stumptner-Cuvelette P, Morchoisne S, Dugast M, Le Gall S, Raposo G, Schwartz O, Benaroch P. 2001. HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proc. Natl. Acad. Sci. U. S. A. 98: 12144-12149. http://dx.doi.org/10.1073/pnas.221256498.
24. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P, Butor C, Silvestri G, Giavedoni LD, Lebon P, Barre-Sinoussi F, Benecke A, Muller-Trutwin MC. 2009. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J. Clin. Invest. 119:3544-3555. http://dx.doi.org/10.1172/JCI40093.
25. Lederer S, Favre D, Walters KA, Proll S, Kanwar B, Kasakow Z, Baskin CR, Palermo R, McCune JM, Katze MG. 2009. Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog. 5:e1000296. http://dx.doi.org/10.1371/journal.ppat.1000296.
26. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, Levin D, Wijeyesinghe S, Makamdop KN, del Prete GQ, Hill BJ, Timmer JK, Reiss E, Yarden G, Darko S, Contijoch E, Todd JP, Silvestri G, Nason M, Norgren RB, Jr, Keele BF, Rao S, Langer JA, Lifson JD, Schreiber G, Douek DC. 2014. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511:601-605. http://dx.doi.org/10.1038/nature13554.
27. Dyavar Shetty R, Velu V, Titanji K, Bosinger SE, Freeman GJ, Silvestri G, Amara RR. 2012. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J. Clin. Invest. 122:1712-1716. http://dx.doi.org/10.1172/JCI60612.
28. Koopman G, Beenhakker N, Nieuwenhuis I, Doxiadis G, Mooij P, Drijfhout JW, Koestler J, Hanke T, Fagrouch Z, Verschoor EJ, Bontrop RE, Wagner R, Bogers WM, Melief CJ. 2013. DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. AIDS 27:2841-2851. http://dx.doi.org/10.1097/QAD.0000000000000047.
29. Abel K, La Franco-Scheuch L, Rourke T, Ma ZM, De Silva V, Fallert B, Beckett L, Reinhart TA, Miller CJ. 2004. Gamma interferon-mediated inflammation is associated with lack of protection from intravaginal simian immunodeficiency virus SIVmac239 challenge in simian-human immunodeficiency virus 89.6-immunized rhesus macaques. J. Virol. 78:841-854. http://dx.doi.org/10.1128/JVI.78.2.841-854.2004.
30. Lehner T, Wang Y, Whittall T, Seidl T. 2011. Innate immunity and HIV-1 infection. Adv. Dent. Res. 23:19-22. http://dx.doi.org/10.1177/0022034511399081.
31. Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, Krishnamurty AT, Chang JT, Adams DJ, Hensley TR, Salter AI, Morgan CA, Duerr AC, De Rosa SC, Aderem A, McElrath MJ. 2012. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(-) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc. Natl. Acad. Sci. U. S. A. 109:E3503-E3512. http://dx.doi.org/10.1073/pnas.1208972109.
32. Mandraju R, Murray S, Forman J, Pasare C. 2014. Differential ability of surface and endosomal TLRs to induce CD8 T cell responses in vivo. J. Immunol.192:4303-4315. http://dx.doi.org/10.4049/jimmunol.1302244.
33. Bowers NL, Helton ES, Huijbregts RP, Goepfert PA, Heath SL, Hel Z. 2014. Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathog. 10:e1003993. http://dx.doi.org/10.1371/journal.ppat.1003993.
34. Harris LD, Tabb B, Sodora DL, Paiardini M, Klatt NR, Douek DC, Silvestri G, Muller-Trutwin M, Vasile-Pandrea I, Apetrei C, Hirsch V, Lifson J, Brenchley JM, Estes JD. 2010. Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. J. Virol. 84:7886-7891. http://dx.doi.org/10.1128/JVI.02612-09.
35. Li B, Stefano-Cole K, Kuhrt DM, Gordon SN, Else JG, Mulenga J, Allen S, Sodora DL, Silvestri G, Derdeyn CA. 2010. Nonpathogenic simian immunodeficiency virus infection of sooty mangabeys is not associated with high levels of autologous neutralizing antibodies. J. Virol. 84:6248-6253. http://dx.doi.org/10.1128/JVI.00295-10.
36. Sodora DL, Allan JS, Apetrei C, Brenchley JM, Douek DC, Else JG, Estes JD, Hahn BH, Hirsch VM, Kaur A, Kirchhoff F, Muller-Trutwin M, Pandrea I, Schmitz JE, Silvestri G. 2009. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat. Med. 15:861-865. http://dx.doi.org/10.1038/nm.2013.
37. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF. 2006. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176:2074-2078. http://dx.doi.org/10.4049/jimmunol.176.4.2074.
38. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. 2001. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461-470. http://dx.doi.org/10.1016/S1074-7613(01)00126-1.
39. Roy S, Katze MG, Parkin NT, Edery I, Hovanessian AG, Sonenberg N. 1990. Control of the interferon-induced 68-kilodalton protein kinase by the HIV-1 tat gene product. Science 247:1216-1219. http://dx.doi.org/10.1126/science.2180064.
40. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586. http://dx.doi.org/10.1126/science.271.5255.1582.
41. Vingert B, Benati D, Lambotte O, de Truchis P, Slama L, Jeannin P, Galperin M, Perez-Patrigeon S, Boufassa F, Kwok WW, Lemaitre F, Delfraissy JF, Theze J, Chakrabarti LA. 2012. HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term. J. Virol. 86:10661-10674. http://dx.doi.org/10.1128/JVI.00056-12.
42. Herbein G, Varin A. 2010. The macrophage in HIV-1 infection: from activation to deactivation? Retrovirology 7:33. http://dx.doi.org/10.1186/1742-4690-7-33.
43. Bergamini A, Bolacchi F, Bongiovanni B, Colizzi V, Cappelli G, Uccella I, Cepparulo M, Capozzi M, Mancino G, Rocchi G. 2000. Human immunodeficiency virus type 1 infection modulates the interleukin (IL)-1beta and IL-6 responses of human macrophages to CD40 ligand stimulation. J. Infect. Dis. 182:776-784. http://dx.doi.org/10.1086/315803.
44. Contreras X, Mzoughi O, Gaston F, Peterlin MB, Bahraoui E. 2012. Protein kinase C-delta regulates HIV-1 replication at an early post-entry step in macrophages. Retrovirology 9:37. http://dx.doi.org/10.1186/1742-4690-9-37.
45. Kornfeld C, Ploquin MJ, Pandrea I, Faye A, Onanga R, Apetrei C, Poaty-Mavoungou V, Rouquet P, Estaquier J, Mortara L, Desoutter JF, Butor C, Le Grand R, Roques P, Simon F, Barre-Sinoussi F, Diop OM, Muller-Trutwin MC. 2005. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J. Clin. Invest. 115:1082-1091. http://dx.doi.org/10.1172/JCI200523006.